Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS).


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
05 2019
Historique:
received: 03 07 2018
accepted: 03 12 2018
pubmed: 19 12 2018
medline: 20 9 2019
entrez: 19 12 2018
Statut: ppublish

Résumé

Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efficacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment. To investigate predictive factors of 6-week and 1-year mortality in patients undergoing salvage TIPS for refractory portal hypertensive bleeding. A total of 144 consecutive patients were retrospectively evaluated. Three logistic regression multivariate models were estimated to individualize prognostic factors for 6-week and 12-month mortality. Log-rank test was used to evaluate survival according to Child-Pugh classes and Bureau's criteria. Mean age 51 ± 10 years, 66% male, mean MELD 18.5 ± 8.3, Child-Pugh A/B/C 8%/38%/54%. TIPS failure occurred in 23(16%) patients and was associated with pre-TIPS portal pressure gradient and pre-TIPS intensive care unit stay. Six-week and 12-month mortality was 36% and 42%, respectively. Pre-TIPS intensive care unit stay, MELD, and Child-Pugh score were independently associated with mortality at 6 weeks. Independent predictors of mortality at 12 months were pre-TIPS intensive care unit stay and Child-Pugh score. In this large cohort of patients undergoing salvage TIPS, MELD and Child-Pugh scores were predictive of short- and long-term mortality, respectively. Pre-TIPS intensive care unit stay was independently associated with TIPS failure and mortality at 6 weeks and 12 months. Salvage TIPS is futile in patients with Child-Pugh score of 14-15.

Sections du résumé

BACKGROUND
Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efficacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment.
AIMS
To investigate predictive factors of 6-week and 1-year mortality in patients undergoing salvage TIPS for refractory portal hypertensive bleeding.
METHODS
A total of 144 consecutive patients were retrospectively evaluated. Three logistic regression multivariate models were estimated to individualize prognostic factors for 6-week and 12-month mortality. Log-rank test was used to evaluate survival according to Child-Pugh classes and Bureau's criteria.
RESULTS
Mean age 51 ± 10 years, 66% male, mean MELD 18.5 ± 8.3, Child-Pugh A/B/C 8%/38%/54%. TIPS failure occurred in 23(16%) patients and was associated with pre-TIPS portal pressure gradient and pre-TIPS intensive care unit stay. Six-week and 12-month mortality was 36% and 42%, respectively. Pre-TIPS intensive care unit stay, MELD, and Child-Pugh score were independently associated with mortality at 6 weeks. Independent predictors of mortality at 12 months were pre-TIPS intensive care unit stay and Child-Pugh score.
CONCLUSIONS
In this large cohort of patients undergoing salvage TIPS, MELD and Child-Pugh scores were predictive of short- and long-term mortality, respectively. Pre-TIPS intensive care unit stay was independently associated with TIPS failure and mortality at 6 weeks and 12 months. Salvage TIPS is futile in patients with Child-Pugh score of 14-15.

Identifiants

pubmed: 30560334
doi: 10.1007/s10620-018-5412-x
pii: 10.1007/s10620-018-5412-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1335-1345

Références

Hepatology. 2004 Oct;40(4):793-801
pubmed: 15382120
Ann Intern Med. 1998 Mar 1;128(5):374-7
pubmed: 9490598
Gastroenterology. 2005 Oct;129(4):1282-93
pubmed: 16230081
J Hepatol. 2011 May;54(5):901-7
pubmed: 21145798
J Crit Care. 2009 Sep;24(3):364-70
pubmed: 19327960
Aliment Pharmacol Ther. 2014 Jun;39(11):1286-300
pubmed: 24738606
Gastroenterology. 2000 Jan;118(1):138-44
pubmed: 10611162
J Hepatol. 2001 Nov;35(5):590-7
pubmed: 11690704
Hepatology. 1981 Mar-Apr;1(2):151-60
pubmed: 7026401
AJR Am J Roentgenol. 2005 Oct;185(4):885-9
pubmed: 16177405
J Hepatol. 2005 Jul;43(1):167-76
pubmed: 15925423
J Hepatol. 2014 May;60(5):962-8
pubmed: 24480619
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
J Hepatol. 2017 Sep 13;68(1):73-81
pubmed: 28918131
Rev Int Hepatol. 1964;14:287-8
pubmed: 14186397
Clin Gastroenterol Hepatol. 2011 Nov;9(11):936-46; quiz e123
pubmed: 21699820
Ann Hepatol. 2015 May-Jun;14(3):380-8
pubmed: 25864219
N Engl J Med. 2000 Jun 8;342(23):1701-7
pubmed: 10841872
J Hepatol. 1998 Mar;28(3):454-60
pubmed: 9551684
J Hepatol. 2012;56 Suppl 1:S13-24
pubmed: 22300462
Hepatology. 2019 Jan;69(1):282-293
pubmed: 30014519
Cardiovasc Intervent Radiol. 1990 Jun-Jul;13(3):200-7
pubmed: 2121348
Cardiovasc Intervent Radiol. 1998 Mar-Apr;21(2):172-5
pubmed: 9502688
Surgery. 1993 Oct;114(4):719-26; discussion 726-7
pubmed: 8211686
Hepatology. 2003 Oct;38(4):1043-50
pubmed: 14512892
N Engl J Med. 2010 Jun 24;362(25):2370-9
pubmed: 20573925
Gut. 2015 Nov;64(11):1680-704
pubmed: 25887380
Gastroenterology. 1995 Jun;108(6):1828-34
pubmed: 7768389
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Lancet. 2014 May 17;383(9930):1749-61
pubmed: 24480518
J Hepatol. 2017 Jul;67(1):184-185
pubmed: 28119010
J Hepatol. 2013 Nov;59(5):1081-93
pubmed: 23811307
Liver Int. 2018 Mar;38(3):412-414
pubmed: 29469210
Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1127-33
pubmed: 17033430
Gut. 1999 Feb;44(2):264-9
pubmed: 9895388
Clin Liver Dis. 2014 Nov;18(4):853-76
pubmed: 25438287
Semin Intervent Radiol. 2005 Dec;22(4):253-65
pubmed: 21326703
Int J Clin Exp Med. 2015 Aug 15;8(8):13464-72
pubmed: 26550283
J Hepatol. 2002 Nov;37(5):703-4
pubmed: 12399244

Auteurs

Sergio Maimone (S)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK. smaimone@unime.it.
Division of Clinical and Molecular Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy. smaimone@unime.it.

Francesca Saffioti (F)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Roberto Filomia (R)

Division of Clinical and Molecular Hepatology, Department of Internal Medicine, University Hospital of Messina, Messina, Italy.

Angela Alibrandi (A)

Department of Economics, Unit of Statistical and Mathematical Sciences, University of Messina, Messina, Italy.

Grazia Isgrò (G)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.

Vincenza Calvaruso (V)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.
Gastroenterology and Hepatology Unit, Di.Bi.M.I.S., University of Palermo, Palermo, Italy.

Elias Xirouchakis (E)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.
Gastroenterology and Hepatology Department, Athens Medical P. Faliron Hospital, Athens, Greece.

Gian Piero Guerrini (GP)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.
Department of Surgery, Ravenna Hospital, Ravenna, Italy.

Andrew K Burroughs (AK)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.

Emmanuel Tsochatzis (E)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.

David Patch (D)

UCL Institute for Liver and Digestive Health and Sheila Sherlock Liver Unit, Royal Free London NHS Foundation Trust and UCL, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH